Robert Iannone, B.S. 1989

“Campus life was great but the greatest learning was absorbed from the city. What a great city! […] It was really the opportunity of our lives. That really was the time of our lives – the best of times in Washington, D.C.”

Robert Iannone, B.S. 1989, wrote these words for an article in the 1988 Cardinal Yearbook. Looking at the success he’s experienced throughout his career, we surmise that Dr. Iannone continued to take advantage of every opportunity he could. More importantly, he has provided opportunities for so many others.

At two pharmaceutical companies, Dr. Iannone has led the development of breakthrough medications for lung cancer. At Merck Research Laboratories, he was a development leader for Keytruda, which is immunotherapy for many cancers, including melanoma and advanced lung cancer. At Astrazeneca Pharmaceuticals/Medimmune, he oversaw the development of Imfinzi, which is immunotherapy for bladder cancer and Stage Three non-small lung cancer.

Most recently, Dr. Iannone served as the head of research and development and the chief medical officer for Immunomedics. In this role, he oversaw all clinical development, regulatory, pre-clinical, translational research, and medical affairs strategies and activities for the company.

On Friday, April 12, 2019, we presented Dr. Iannone with an Alumni Achievement Award. Please join us in congratulating Dr. Iannone for his incredible work as an alumnus of The Catholic University of America. Thank you, Dr. Iannone, for developing the medication that so many people need to live their best.

The Catholic University of America is only a small piece of Robert's incredible story, but we are proud to be a University that has a tremendous impact through the accomplishments of our alumni. We ask you to consider making a gift today so that we can continue to educate Cardinals who will go on to make a positive impact on our world.